OncoGenex - Riesige Produktpipeline - TOP !

der Markt sieht es anscheinend anders ;-)...


@don

und wird es hier dippen, was meinst du ?

... ich beobachte in letzter Zeit immer häufiger, dass Firmen trotz guter Zahlen und positiven Analystenmeinungen abgestraft werden.

ist eigentlich immer ein guter Kontra-Indikator.

Vor diesem Hintergrund müsste man jetzt eigentlich kaufen...

 

OncoGenex Fourth Quarter 2015 Conference Call 4.30pm

ir.oncogenex.com/events.cfm

raus !!

ir.oncogenex.com/releasedetail.cfm?ReleaseID=959744

man könnte meinen,der text wurde von einem deutschen geschrieben,

nur meine meinung

seekingalpha.com/article/...5-results-earnings-call-transcript





OncoGenex Pharmaceuticals' (OGXI) CEO Scott Cormack on Q4 2015 Results - Earnings Call Transcript
Mar. 9, 2016 9:39 PM ET| About: OncoGenex Pharmaceuticals Inc. (OGXI)
SA Transcripts SA Transcripts⊕Follow(11,878 followers)
We cover over 5K calls/quarter
Send Message|Website(37,756 clicks)
Operator

Good day ladies and gentlemen and welcome to the OncoGenex fourth quarter 2015 conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions]. As a reminder, this conference is being recorded.

I would like to introduce your host for today's conference, Mr. Jim DeNike, Senior Director of Corporate Communications. Sir, please begin.

Jim DeNike

Thanks Vance and thanks everyone for joining us. With me today from OncoGenex are Scott Cormack, President and Chief Executive Officer, John Bencich, Chief Financial Officer and Dr. Cindy Jacobs, our Chief Medical Officer.

Before we begin, I would like to remind everyone that today's conference call contains forward-looking statements based on current expectations. These statements are only predictions and actual results may vary materially from those projected. Please refer to OncoGenex documents filed with the SEC concerning factors that could affect the company, copies of which are available on the website.

I will now turn the call over to Scott.

Scott Cormack

Thanks, Jim. On today's call, we will provide an update on our clinical development programs with near-term milestones that we believe could create significant value for the company over the next 12 months. Following our program update, John will provide an overview of our financial position that includes steps we have taken to further strengthen our balance sheet.

These steps have extended our cash runway for additional six months, which now takes us into the third quarter of 2017. Our cash position will allow us to execute on our clinical development plans, including reporting of two Phase III clinical trials, two Phase II clinical trials and preparation of an investigational new drug application so that it would be submission ready for the FDA.

Let me take a few minutes to walk you through the status of each of these programs starting with the Apatorsen IND in non-muscle invasive bladder cancer. Our Apatorsen compound is a subject of four ongoing clinical studies designed to evaluate whether inhibition of Hsp27 can lead to improved treatment outcomes for cancer patients. The trials underway are designed to evaluate Apatorsen in bladder, lung and prostate cancer in combination with various treatments. They are being conducted in order to provide information for designing future Phase III trials and could be used as supportive studies for registration purposes.

Starting with bladder cancer. We have data in hand from two completed studies in advanced metastatic and non-muscle invasive bladder cancer. These data include results presented at ASCO 2015 from the Phase II Borealis-1 trial in which patients who were defined as having risk for poor survival outcome and received Apatorsen in combination with chemotherapy experienced a 27% reduction in risk of death compared to patients receiving chemotherapy alone. Data has also been presented from a Phase I trial evaluating patients with non-muscle invasive bladder cancer in which 33% of the patients treated had no pathologic evidence of disease following treatment with Apatorsen.

Based on these encouraging findings, we submitted a pre-IND package to the FDA for evaluation of intravesically administered Apatorsen in combination with BCG treatment in patients with non-muscle invasive bladder cancer. We recently received feedback from the FDA regarding our proposed trial protocol under this newly proposed IND. I am pleased to report that the FDA had no objection to our proposed study population or classification of subpopulations in the study design and concluded that the proposed definitions of primary and secondary endpoints were acceptable.

page 1 / 6 | Next »

wieso verkauft der die Zahlen??

du schenkst denen zuviel Beachtung !!!


schau doch selber nach..


Cash, cash equivalents, short term investments and restricted cash

$55,458M


bei ca. 30M Shares sind ca. $1,94 ohne Pipeline !!!

und hier

Total operating expenses for the fourth quarter and year ended December 31, 2015 were $9.5 million and $36.9 million, respectively. Net loss for the fourth quarter and year ended December 31, 2015 was $1.7 million and $16.8 million, respectively.
          §

aber dass die alle wieder blind hier reingehen, da brauchen wir wohl nicht drüber reden


sieht man ja gerade wieder,öffnen bestimmt wieder mal mit GAP-UP und
wundern sich nachher, warum es fällt !!


Leute der Kurs wird drüben gemacht , kauft doch nicht immer über Pari !!


SK $0.77 = 0,70€

Das waren doch gar nicht mal so schlechte Zahlen.

Bin seit gestern bei OncoGenex dabei.

Ein nettes Accessoire für meinen Risiko-Anteil im Depot.

u.a. mit Great Basin Scientific, Aeterna Zentaris, Cara Therapeutics (heute vor Börsenstart gibt´s die Zahlen), Epigenomics und Peregrine Pharma, außerdem Enphase Energy, Bombardier und Eurobank Ergasias.

sich aus eurer sicht noch ein einstieg???

hier auch mal gespannt, bis wohin die Euphoriewelle trägt...

Der Dollar fällt gleich

push mal lol

300 Shares ;-)

www.nasdaq.com/symbol/ogxi/premarket

deshalb bleib ich schön brav an der Seitenlinie!
Es fällt mir zwar schwer, aber ich glaube, es gibt noch bessere Gelegenheiten zum Einstieg!  

schöner langsamer Anstieg

ohne Volumen ist nur Kosmetik!
Ich warte weiter auf interessante Kurse.  

der Hai von sd stockt die ganze Zeit auf, weil er hofft, dass die Leute drauf aufspringen...;-)


e hat halt noch nicht den erwünschten Verlauf, schwaches Vol.

Die Initiatoren dieses Pushversuchs haben sich wohl mehr versprochen. Sie haben nicht bedacht, dass Lemminge noch im Winterschlaf sind! LOL

worum es geht?

mal was positives zur Aktie. Schau an wie fleissig du pushen kannst... kennt man ja nicht  

thread !!

ja man hat hier aber schon noch ein bisschen Zeit zum sammeln...


nur wird zu sehr getrommelt, weil einer schon dick drin ist...sucht halt Käufer, obwohl
man hier bis H2 bzw Q3 Zeit hat für die Ergebnisse ;-)